Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy (Q79301471)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14623059%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

title

Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14623059%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

main subject

Paget's disease of bone

1 reference

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

3 April 2024

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14623059%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

Marelise E. M W. Eekhoff

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623059

3 April 2024

Aeilko H. Zwinderman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623059

3 April 2024

Dorien M. A D. Haverkort

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623059

3 April 2024

Serge C. L M. Cremers

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623059

3 April 2024

Neveen A. T. Hamdy

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623059

3 April 2024

Socrates E. Papapoulos

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623059

3 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14623059

3 April 2024

publication date

1 November 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14623059%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

21 December 2019

https://api.elsevier.com/content/article/PII:S875632820300276X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

https://api.elsevier.com/content/article/PII:S875632820300276X?httpAccept=text/plain

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

3 April 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14623059%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14623059%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14623059%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

831-838

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14623059%20AND%20SRC:MED&resulttype=core&format=json

Guidelines on the management of Paget's disease of bone

21 December 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Goals of treatment for Paget's disease of bone

3 April 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Short-term intravenous therapy with Neridronate in Paget's disease

3 April 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

The management of Paget's disease of bone

3 April 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease

3 April 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate

3 April 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Discussion: Newer bisphosphonates in the treatment of Paget's disease of bone: where we are and where we want to go.

3 April 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Ibandronate treatment in Paget's disease of bone

3 April 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study

3 April 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).

3 April 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Alendronate in the treatment of Paget's disease of bone

3 April 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Tiludronate therapy for Paget's disease of bone

3 April 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group

3 April 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Tiludronate. A new treatment for an old ailment: Paget's disease of bone

3 April 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Paget's disease of bone: clinical, pathogenetic and therapeutic aspects

3 April 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone

3 April 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate

3 April 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Pamidronate in the treatment of Paget's disease.

3 April 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.

3 April 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study

3 April 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Paget's disease of bone treated in five days with AHPrBP (APD) per Os

3 April 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

A single infusion of Pamidronate (APD) in Paget's disease of bone

3 April 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Short-term therapy with oral olpadronate in active Paget's disease of bone

3 April 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate

3 April 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Preliminary study of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile

3 April 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo

3 April 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

A specific method for the analysis of hydroxyproline in tissues and urine

3 April 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Duration of response with oral clodronate in Paget's disease of bone.

3 April 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another.

3 April 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone

3 April 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study.

3 April 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Duration of effect of oral diphosphonate therapy in Paget's disease of bone

3 April 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Determinants of remission of Paget's disease of bone

3 April 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

Therapeutic strategy in Paget's disease of bone.

3 April 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2003.03.001

3 April 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14623059%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference